MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...

MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure ...

said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers. The company said its EscharEx treatment had previously demonstrated its ability to effectively and ...

Take steps to improve blood flow to legs and help prevent venous conditions such as varicose and spider veins. Suggestions ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...

Tactile Systems Technology (NASDAQ:TCMD – Get Free Report) is projected to release its earnings data after the market closes on Tuesday, February 18th. Analysts expect Tactile Systems Technology to ...

Medical experts emphasize that recognizing worsening symptoms early can make a significant difference in treatment outcomes. The nature of ulcer pain often changes as the condition progresses.